Literature DB >> 6205581

Gastric stapling for morbid obesity: gastrointestinal response in a rat model.

E A Young, M M Taylor, M K Taylor, A S McFee, O L Miller, C A Gleiser.   

Abstract

The adaptive response of the gastrointestinal tract to gastric stapling was studied in a Zucker (fafa) genetically obese rat model. The effects of gastric stapling in rats with a Roux-en-Y gastrojejunostomy were compared to Roux-en-Y and intact controls. Rats (225 to 275 g) were divided into three groups: group I (GI), Roux-en-Y, stapled, ad libitum fed; group II, Roux-en-Y, unstapled; and group III, intact (laparotomy only). Groups II and III were further subdivided into group IIA (GIIA) and group IIIA (GIIIA), pair-fed to GI; and group IIB (GIIB) and Group IIIB (GIIIB), fed ad libitum. All rats were fed a diet of liquid rat formula and rat food (50:50 cal ratio). After 2 wk rats were killed and the liver, pancreas, and stomach removed, weighed, and tissue taken for histology. The intestine was divided into three segments corresponding to the excluded segment (1, duodenum), transposed segment (2, jejunum), and ileal segment (3), with tissue taken for histology. Liver lipid, pancreatic amylase, serum amylase and gastrin, and intestinal mucosal protein and DNA were measured. Weight gain, g/14 days, was: GI, 24.1 +/- 7.8; GIIA, 17.0 +/- 2.0; GIIB, 42.6 +/- 4.8; GIIIA, 17.6 +/- 4.7; GIIIB, 54.6 +/- 8.9. All rats were in positive N balance. Liver weight and lipid were similar in all groups. Pancreatic mass was significantly increased in all Roux-en-Y animals, while amylase activity per g tissue was significantly less than in intact animals. Stapled rats had atrophy of the glandular portion of the stomach, decreased stomach mucosal weight, and lower serum gastrin concentration compared with all other rats (p less than 0.01). In stapled rats, segment weight and mucosal weight were lower in the excluded segment, and higher in the transposed segment, compared to all other rats. Tissue pathology was found only in stapled rats: gastric atrophy, focal fibrosis of gastric wall, peritonitis, minimal to mild multifocal hepatitis, and mild periductal fibrosis of the pancreas. There are significant early adaptive and pathological changes after gastric stapling in the rat.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6205581     DOI: 10.1093/ajcn/40.2.293

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  6 in total

1.  Gastric bypass surgery does not increase susceptibility to Helicobacter pylori infection in the stomach of rat or mouse.

Authors:  Björn Stenström; Kirsti Løseth; Lars Bevanger; Erik Sturegård; Torkel Wadström; Duan Chen
Journal:  Inflammopharmacology       Date:  2005       Impact factor: 4.473

2.  Larrad biliopancreatic diversion in Sprague-Dawley rats. Analysis of weight loss related to food intake.

Authors:  Hugo Mendieta-Zerón; Alvaro Larrad-Jiménez; Gema Frühbeck; Katia Da Boit; C Diéguez
Journal:  Obes Surg       Date:  2008-10-15       Impact factor: 4.129

3.  Mechanisms of glucose homeostasis after Roux-en-Y gastric bypass surgery in the obese, insulin-resistant Zucker rat.

Authors:  Katia Meirelles; Tamer Ahmed; Derek M Culnan; Christopher J Lynch; Charles H Lang; Robert N Cooney
Journal:  Ann Surg       Date:  2009-02       Impact factor: 12.969

4.  Secondary hyperparathyroidism and osteopenia in women following gastric exclusion surgery for obesity.

Authors:  J L Shaker; A J Norton; M F Woods; M D Fallon; J W Findling
Journal:  Osteoporos Int       Date:  1991-06       Impact factor: 4.507

Review 5.  Rat models for bariatric surgery and surgery for type 2 diabetes mellitus.

Authors:  Sheetal Bharat Mistry; Juan J Omana; Subhash Kini
Journal:  Obes Surg       Date:  2009-03-06       Impact factor: 4.129

6.  Roux-en-Y gastric bypass enhances energy expenditure and extends lifespan in diet-induced obese rats.

Authors:  Nicholas Stylopoulos; Alison G Hoppin; Lee M Kaplan
Journal:  Obesity (Silver Spring)       Date:  2009-06-25       Impact factor: 5.002

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.